Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov;9(4):270-274.
doi: 10.20407/fmj.2022-034. Epub 2023 Aug 28.

The efficacy of prophylactic prochlorperazine injections at the initiation of opioid injections in preventing opioid-induced nausea and vomiting among patients with end-stage cancer

Kazuki Imai  1   2   3 , Akihiko Futamura  2   3 , Miyo Murai  2 , Akihiro Ito  2 , Norimasa Tsuzuki  2 , Masanobu Usui  2
Affiliations

The efficacy of prophylactic prochlorperazine injections at the initiation of opioid injections in preventing opioid-induced nausea and vomiting among patients with end-stage cancer

Kazuki Imai et al. Fujita Med J. 2023 Nov.

Abstract

Objectives: Antiemetics have been widely recommended for treating opioid-induced nausea and vomiting (OINV). According to a previous study, the use of prophylactic prochlorperazine at the initiation of treatment with oral oxycodone was ineffective in preventing OINV. This study examined whether prochlorperazine injection prevents OINV and induces drowsiness in patients with end-stage cancer (a different patient population from the previous study).

Methods: Patients with end-stage cancer who received opioid injections for more than 5 days between April 2017 and March 2020 were classified into two groups: the opioid and prochlorperazine injection group and opioid alone group. Their systemic conditions were evaluated on the basis of the performance status and the palliative performance scale, a prognostic indicator.

Results: Of 325 patients who received opioid treatment during the study period, 156 patients met the inclusion criteria. Of these, 103 patients and 53 patients were classified into the opioid and prochlorperazine injection group (prochlorperazine) and opioid alone groups (placebo) , respectively. There was no significant difference in characteristics, age, gender, performance status, or palliative performance scale results between the 2 groups. OINV developed in 4 patients in the opioid and prochlorperazine injection groups and in 1 patient in the opioid alone group. Given that sleep disturbance develops in many patients with end-stage cancer who had a specific condition, it is difficult to conclude regarding the relationship between prochlorperazine injection and drowsiness, although this study examined this relationship.

Conclusions: As with the previous study, prophylactic prochlorperazine injection was ineffective in preventing OINV in patients who received opioid injections.

Keywords: Morphine; OINV; Oxycodone; Prochlorperazine injection.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest to declare for this article.

Figures

Figure 1
Figure 1
Eligibility criteria
Figure 2
Figure 2
Screening of the study patients
Figure 3
Figure 3
Palliative Performance Scale
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Fischer DJ, Villines D, Kim YO, Epstein JB, Wilkie DJ. Anxiety, depression, and pain differences by primary cancer. Support Care Cancer 2010; 18: 801–810. - PMC - PubMed
    1. Bruera E, Kim HN. Cancer pain. JAMA 2003; 290: 2476–2479. - PubMed
    1. Davis MP, Walsh D. Epidemiology of cancer pain and factors influencing poor pain control. Am J Hosp Palliat Care 2004; 21: 137–142. - PubMed
    1. Wiffen PJ, Derry S, Moore RA. Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. Cochrane Database Syst Rev 2014; 2014: CD011056. - PMC - PubMed
    1. Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev 2006; 32: 304–315. - PubMed